What Is Cagrilintide + Semaglutide (CagriSema)? CagriSema is an investigational fixed-dose combination of two distinct molecular agents: Cagrilintide — a long-acting synthetic amylin analog targeting AMYR1–3 receptors — and Semaglutide — a GLP-1 receptor agonist with established pharmacological characterization. The combination engages two separate but complementary neuroendocrine axes involved in appetite regulation, postprandial glucose management, and metabolic signaling, currently under active Phase III clinical investigation sponsored by Novo Nordisk A/S.

Mechanism of Action Semaglutide binds selectively to GLP-1 receptors located in the pancreas, hypothalamus, and brainstem, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Cagrilintide acts via amylin receptors (AMYR1–3) in the brainstem and hypothalamus to enhance satiety signaling and further delay gastric emptying through pathways distinct from GLP-1 receptor activation. The dual receptor engagement produces additive effects on the gut-brain axis, with each agent operating through independent but mechanistically complementary downstream cascades.

Research & Clinical Trial Data CagriSema is currently under evaluation across multiple registered Phase III trials:

• REDEFINE 1 (NCT05567796) — Phase IIIa; mean body weight reduction outcomes published in The New England Journal of Medicine
• NCT07011667 — Long-term weight maintenance; Active, not recruiting
• NCT06131372 — Chronic kidney disease + T2D cohort; Phase II, Completed
• NCT07253285 — Pediatric population; Phase III, Recruiting

Purity & Quality Reference-grade material. Certificate of Analysis available per batch. Regulatory status: not approved by FDA or EMA for general therapeutic use as of current listing date.

Cagrilintide Class: Long-acting amylin analog | Semaglutide Class: GLP-1 receptor agonist | Administration: Subcutaneous | Sponsor: Novo Nordisk A/S | Storage: 2–8°C refrigerated, protect from light